Mirion Technologies, Inc. (MIR) · Oct 27, 2026 · Earnings
Beat — Revenue $277.8M vs ~$275.4M consensus; adjusted EPS $0.12 in line
Mirion’s Q3 earnings were narrowly ahead on revenue, while nuclear orders accelerated and full-year adjusted free-cash-flow guidance was raised.
Mirion is in a post-acquisition nuclear-growth buildout: Certrec and Paragon have expanded its nuclear-power offering, while the company continues selling radiation detection and monitoring solutions across nuclear, medical, defense, and research markets.
The quarter modestly beat the financial bar. Revenue reached $277.8 million versus published consensus of roughly $275.4 million, while adjusted EPS was $0.12, essentially matching the $0.12 expectation. That makes this a narrow earnings beat, not a broad upside surprise.
| Metric | Q3 2026 | Q3 2025 | Versus expectation |
|---|---|---|---|
| Revenue | $277.8M (Income Statement) | $223.1M | ~$275.4M consensus |
| Adjusted EBITDA | $64.8M (Adjusted EBITDA reconciliation) | $52.4M | — |
| Adjusted EBITDA margin | 23.3% (Adjusted EBITDA reconciliation) | 23.5% | — |
| Adjusted EPS | $0.12 (Adjusted net income reconciliation) | $0.12 | ~$0.12 consensus |
| GAAP EPS | $0.03 (Income Statement) | $0.01 | — |
| Operating cash flow, nine months | $136.6M (Cash Flow statement) | $70.3M | — |
| Adjusted free-cash-flow guidance | $170M–$185M (Guidance) | — | Previously $155M–$175M |
GAAP net income was $7.8million in the third quarter, a 151.6% increase compared to GAAP net income of $3.1million in the same period in 2025. Adjusted EBITDA was $64.8million in the third quarter, a 23.7% increase from $52.4million in the same period last year.
The more important signal is demand, not the small revenue beat. Orders excluding Paragon and Certrec rose 62% year over year to $340 million, including a 105% increase in nuclear-power-related orders. That supports the company’s claim that nuclear-fleet reinvestment is translating into future workload, although orders still have to convert into revenue.
Organic growth is finally showing the expected inflection. Management said organic revenue grew 6.5% in Q3 and expects mid-to-high-teens organic growth in Q4. 〔0〕 This is meaningful because the pre-filing story already assumed a stronger second half; the filing provides early evidence of that acceleration rather than introducing the thesis from scratch.
Cash generation improved enough to lift the full-year target. Adjusted free-cash-flow guidance increased to approximately $170 million–$185 million from $155 million–$175 million, and conversion guidance rose to 60%–63% from 54%–58%. Nine-month operating cash flow also nearly doubled to $136.6 million, though the company remains meaningfully leveraged with $444.0 million of non-current debt and $757.6 million of convertible debt (Balance Sheet).
Bottom line: This is a modest beat with a more constructive operational message: nuclear orders, organic growth, and cash generation are all improving together. The result advances the second-half recovery thesis, but the cleanest proof still depends on converting the order surge into Q4 revenue and profit.
Q4 report, expected early February 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!